NFE2L2 and lung cancer: Osimertinib exposure leads to an upregulation of suppressor of cytokine signaling 3 (SOCS3), which competes with NRF2 for KEAP1 binding, diminishing NRF2 degradation, activating antioxidant pathways, and contributing to osimertinib resistance in lung cancer [19].